Industry Rating - The report rates the pharmaceutical industry as "Leading" [1] Core Insights - The report highlights that the recent national procurement has been stable, with a high selection rate of 93%, indicating a positive outlook for innovative companies in the sector [4][5] - The market sentiment has improved, driven by significant business development (BD) transactions, suggesting a continuation of the positive trend in 2026 despite potential short-term volatility [4] - The report emphasizes the importance of focusing on fundamentals and valuations when selecting stocks, particularly undervalued innovative companies that have been overlooked during market fluctuations [4] Summary by Sections Market Performance - The Hang Seng Index rose by 1.3% and the Hang Seng Healthcare Index increased by 5.0%, outperforming the broader market [4][6] - Sub-sectors such as biopharmaceuticals and CXO both saw a growth of 7.4% [6] Institutional Holdings - As of February 10, 2026, domestic institutional holdings through Hong Kong Stock Connect slightly decreased to 22.2%, while foreign holdings increased to 39.7%, indicating a shift towards more positive sentiment among foreign investors [32] - Key increases in holdings were noted in leading CXO companies benefiting from demand recovery, such as Tigermed and WuXi AppTec [37][38] Valuation Overview - The report provides a valuation summary for various companies, with notable buy ratings for AstraZeneca, BeiGene, and others, indicating strong growth potential [3] - The average price-to-earnings (P/E) ratio for the healthcare sector is reported at 28.4 times, with specific segments like biopharmaceuticals at 13.1 times [16] Sales Trends - The report notes a 1% year-on-year decline in China's pharmaceutical market sales for 2025, with significant variations across different sales channels [5] - Public hospitals accounted for the largest market share but experienced a 2.1% decline, while retail pharmacies saw a 2.4% increase, driven by online sales growth [5] Procurement Insights - The recent national procurement round involved 316 commonly used drugs, with a high participation rate and diverse product offerings, ensuring stable clinical supply [5] - The procurement process has been refined to enhance quality and reliability, with stricter requirements for participating companies [5]

Group 1 - The core point of the article highlights that southbound funds reduced their holdings in Jinxin Reproductive Medicine (01951.HK) by 4.8555 million shares on February 11, with a total net reduction of 5.5385 million shares over the last five trading days [1] - Over the past 20 trading days, southbound funds increased their holdings on 14 days, resulting in a cumulative net increase of 19.0741 million shares [1] - As of now, southbound funds hold 1.466 billion shares of Jinxin Reproductive Medicine, accounting for 53.15% of the company's total issued ordinary shares [1] Group 2 - Jinxin Reproductive Medicine Group Limited is an investment holding company primarily providing in vitro fertilization (IVF) services [1] - The company offers a range of services through its subsidiaries, including assisted reproductive services, management services, ambulatory surgical center facility services, auxiliary medical services, and maternal and pediatric medical services, as well as the sale of medical consumables and equipment [1] - The company primarily operates in China and the United States [1]

Core Viewpoint - Southbound funds have increased their holdings in Jinxin Fertility (01951.HK), indicating growing investor interest in the company and its services in the assisted reproductive sector [1] Group 1: Shareholding Activity - On February 10, southbound funds increased their holdings by 679,000 shares of Jinxin Fertility [1] - Over the past five trading days, there have been four days of net increases in holdings, totaling 3.4365 million shares [1] - In the last 20 trading days, there were 14 days of net increases, amounting to 20.0356 million shares [1] - Currently, southbound funds hold 1.471 billion shares of Jinxin Fertility, representing 53.33% of the company's issued ordinary shares [1] Group 2: Company Overview - Jinxin Fertility Medical Group Limited is an investment holding company primarily providing in vitro fertilization (IVF) services [1] - The company offers a range of services through its subsidiaries, including assisted reproductive services, management services, mobile surgical center facilities, auxiliary medical services, and obstetrics and pediatrics medical services [1] - Jinxin Fertility operates mainly in China and the United States, also engaging in the sale of medical consumables and equipment [1]

Group 1 - Southbound funds reduced their holdings in Jinxin Fertility (01951.HK) by 4.7445 million shares on February 9 [1] - Over the past 5 trading days, southbound funds increased their holdings on 4 days, with a total net increase of 13.3475 million shares [1] - In the last 20 trading days, there were 13 days of net increases in holdings by southbound funds, totaling 13.3616 million shares [1] - Currently, southbound funds hold 1.47 billion shares of Jinxin Fertility, accounting for 53.31% of the company's issued ordinary shares [1] Group 2 - Jinxin Fertility Medical Group Limited is an investment holding company primarily providing in vitro fertilization (IVF) services [1] - The company offers assisted reproductive services, management services, mobile surgical center facility services, auxiliary medical services, obstetrics and pediatrics medical services, as well as sales of medical consumables and equipment [1] - The company primarily operates in China and the United States [1]

Core Insights - The trend of "foreigners seeking medical treatment in China" has surged since 2026, with significant attention on the efficiency and cost-effectiveness of Chinese healthcare compared to Western countries [1][15][17] - The number of international patients in key Chinese hospitals reached 1.28 million in 2025, a 73.6% increase from three years prior, indicating a growing ecosystem for international medical services [1][15] Group 1: Patient Experiences - A foreign patient, Andre, shared his experience of receiving quick and efficient treatment in a Chinese hospital, highlighting a 30-minute visit for a fishbone removal that cost only 300 RMB, contrasting sharply with longer wait times and higher costs in Australia [2][3][4] - The affordability of medical services in China is a significant draw for international patients, with cost comparisons showing treatments in China can be up to 10 times cheaper than in countries like the US and Turkey [15][16] Group 2: Medical Professionals' Perspectives - Chinese medical professionals are increasingly confident in their ability to treat international patients, as evidenced by a case where a Filipino doctor sought treatment for a patient in China, showcasing the growing recognition of Chinese medical expertise [6][7][9] - The use of advanced technologies and multi-disciplinary teams in Chinese hospitals enhances the quality of care, making it appealing for foreign patients [7][9] Group 3: Institutional Insights - The Chinese healthcare system is evolving to attract more international patients, with private hospitals seen as key players in this shift, as they can offer tailored services and flexibility that public hospitals may not [10][11] - Despite the growing interest, there is still a significant gap in brand recognition for Chinese hospitals internationally, indicating a need for improved marketing and outreach strategies [11][12] Group 4: Cost Comparisons - The cost of medical services in China is significantly lower than in many Western countries, with examples showing that a consultation in China can cost as little as 4 USD compared to hundreds or thousands in the US [16][17] - The structured pricing in China's public healthcare system contributes to its affordability, making it an attractive option for international patients seeking quality care at lower costs [16][17]

Core Viewpoint - The trend of "foreigners seeking medical treatment in China" has surged since 2026, with significant attention on the efficiency, quality, and cost-effectiveness of Chinese healthcare compared to Western countries [2][19]. Group 1: Growth in International Patients - In 2025, key foreign-related hospitals in China received 1.28 million international patients, a 73.6% increase from three years prior [2]. - By 2024, 850 medical institutions across 57 cities in China had established international medical services, forming a growing ecosystem [2]. Group 2: Patient Experiences - Foreign patients have shared positive experiences regarding the speed and efficiency of medical services in China, with one Australian patient noting a 30-minute treatment for a fishbone incident costing only 300 RMB [4][5]. - Comparatively, similar treatments in countries like Australia and Turkey can cost significantly more, highlighting the cost advantage of Chinese healthcare [19][20]. Group 3: Medical Professionals' Perspectives - Chinese medical professionals express confidence in their ability to treat foreign patients, noting that international patients are increasingly willing to seek treatment in China without hesitation [8][12]. - The use of advanced technologies and multi-disciplinary teams in Chinese hospitals enhances the quality of care provided to international patients [10][12]. Group 4: Brand and Policy Challenges - Despite the growing number of international patients, there is a need for improved brand recognition and marketing of Chinese hospitals to attract more foreign patients [14][16]. - The private healthcare sector is seen as a potential leader in accommodating international patients, while public hospitals should focus on domestic needs [16][17]. Group 5: Cost Comparison - The cost disparity between Chinese and Western medical services is significant, with reports indicating that treatment costs in China can be up to 10 times lower than in countries like the U.S. and Australia [19][20]. - The average outpatient cost in China is reported to be 361 RMB, while the U.S. healthcare expenditure per capita is significantly higher, reflecting the efficiency of China's public healthcare system [20].

研究报告 Research Report 9 Feb 2026 香港医疗 Hong Kong Health Care 医药行业周报（2026.02.02-2026.02.06）：市场情绪回暖；看好基本面表现强劲的创新药产业链龙头 Healthcare Weekly (2026.02.02-2026.02.06): Market Sentiment Warms; Bullish on Leaders in Innovative Drug Chain with Strong Fundamentals [Table_yemei1] 观点聚焦 Investment Focus | [Table_Info] | | | | | --- | --- | --- | --- | | 股票名称 | 评级 | 股票名称 | 评级 | | 百济神州 | Outperform 华润医药 | | Outperform | | 京东健康 | Outperform 国药控股 | | Neutral | | 药明生物 | Outperform 映恩生物 | | Outperform | | 信达生物 | Outperform 金斯瑞生物科 ...

节前医美进入"拉满模式"：启动更早、客流更密 "今年忙得特别早。"这是多位医美从业者对今年春节前市场的直观判断。 "元旦假期前就已经明显忙起来了，连喝口水的时间都没有。"西安国际医学中心医院整形美容 科主任孙峰向财联社记者表示，其所在的眼整形门诊，一上午面诊人数最多能达到45人，"以 我个人的排期为例，一天四五台是常态，年前早就约满了，部分顾客的手术已经排至春节后 了。" 晚上九点，成都一家轻医美诊所的候诊区仍灯火通明。玻璃门外，商场人流已明显减少；玻璃 门内，取号屏上的数字却仍在滚动刷新，前台不时提醒，"后面的客人稍等几分钟。" 财联社记者近日通过调研、多方采访了解到，1月份以来，全国各地医美机构逐渐迎来客流高 峰期的同时，医美消费者的需求也在发生结构性变化。 从机构排期、门诊接诊量到营业时间延长，多项指标均显示，节前医美市场已提前进入"满负 荷运转"状态。多位医美机构负责人、整形科医生在接受财联社记者采访时表示， 今年节前医 美消费热潮启动时间明显早于往年，且客流高峰持续时间更长。 这场热潮并非单纯的周期性回暖，多位受访者表示， 轻医美项目取代传统手术类项目，成为节 前消费的绝对主流；项目选择更趋精准化、 ...

Investment Rating - The report provides an "Outperform" rating for multiple companies in the healthcare sector, including BeiGene, JD Health, WuXi Biologics, and others, indicating a positive outlook for these stocks [1]. Core Insights - The macro and industry environment is improving due to the resolution of policy uncertainties, the release of significant clinical data, and a resurgence in global M&A activity, leading to a notable increase in investor sentiment towards innovative drugs for 2026 [4][11]. - In oncology, the PD-1/VEGF dual antibody approach is transitioning from "mechanism validation" to "clinical and industrial resonance," with multiple global Phase III trials underway, expected to catalyze approvals and data releases within the year [5][17]. - The metabolic sector is seeing growth in the cash-pay market for GLP-1 drugs, driven by limited insurance coverage and high out-of-pocket costs, prompting companies to enhance accessibility through direct sales and pricing adjustments [6][25]. - In the autoimmune space, there is a growing concentration risk among major products from multinational corporations (MNCs), with new antibody platforms expected to yield significant data in 2026, potentially leading to new business development opportunities [7]. - The central nervous system (CNS) investment focus remains on advancing Aβ monoclonal antibody treatments, with key data expected to open up early intervention market opportunities [9]. Summary by Sections Oncology - The PD-1/VEGF dual antibody's clinical and industrial certainty is strengthening, with major companies conducting multiple global Phase III trials across high-value indications [17]. - The Pan-RAS precision therapy is entering a realization phase, with key Phase III data expected in 2026 for pancreatic cancer and NSCLC [22]. Metabolic - The cash-pay market for GLP-1 drugs is expanding due to limited insurance coverage, with companies like Eli Lilly and Novo Nordisk adopting different direct-to-consumer strategies to enhance accessibility [25][26]. - Small nucleic acid therapies are expected to upgrade treatment paradigms, showing competitive data in weight loss and safety profiles when combined with GLP-1 [30]. Autoimmune - MNCs are increasingly reliant on a few blockbuster products, with structural opportunities arising from new antibody platforms expected to report data in 2026 [7]. - The trend towards oral formulations in autoimmune diseases is gaining traction, offering advantages in adherence and competitive differentiation [7]. CNS - The focus in CNS remains on Aβ monoclonal antibody treatments, with advancements expected to shift treatment towards earlier intervention populations [9]. - New delivery methods, such as systemic administration of small nucleic acids, are being explored as complementary approaches [9].

Group 1 - The core point of the article highlights that southbound funds have increased their holdings in Jinxin Reproductive Medicine (01951.HK) by 2.947 million shares on February 5, with a total net increase of 17.619 million shares over the last five trading days [1] - Over the past 20 trading days, southbound funds have increased their holdings on 13 days, resulting in a cumulative net increase of 16.8501 million shares [1] - As of now, southbound funds hold 1.474 billion shares of Jinxin Reproductive Medicine, accounting for 53.45% of the company's total issued ordinary shares [1] Group 2 - Jinxin Reproductive Medicine Group Limited is an investment holding company primarily providing in vitro fertilization (IVF) services [1] - The company offers a range of services through its subsidiaries, including assisted reproductive services, management services, mobile surgical center facility services, auxiliary medical services, obstetrics and pediatrics medical services, as well as the sale of medical consumables and equipment [1] - The company's services are mainly provided in China and the United States [1]